We help you, help your patients live healthier lives

Lifeline Pharmaceuticals is a national distributor of specialty, brand and generic pharmaceuticals, vaccines and injectables with a focus on the alternate site surgery market. Lifeline is an authorized distributor of record (ADR) for more than 40,000 products by major pharmaceutical manufacturers including Hospira, Baxter, Sandoz, Akorn, Merck, West-Ward, American Regent, APP Pharmaceuticals, Pfizer and many more.

 

SURGERY DRUGS

ANTIBIOTICS

·         Ampicillin and Sulbactam for Injection, USP
·         Azithromycin for Injection, USP
·         Cefazolin for Injection, USP
·         Cefotaxime Sodium (Claforan™)
·         Ceftazidime for Injection, USP (Tazicef™)
·         Ceftriaxone for Injection, USP
·         Cefuroxime for Injection, USP
·         Ciprofloxacin Injection, USP
·         Ciprofloxacin in 5% Dextrose Injection, USP
·         Clindamycin Injection, USP
·         Ampicillin and Sulbactam for Injection, USP
·         Azithromycin for Injection, USP
·         Cefazolin for Injection, USP
·         Cefotaxime Sodium (Claforan™)
·         Ceftazidime for Injection, USP (Tazicef™)
·         Ceftriaxone for Injection, USP
·         Cefuroxime for Injection, USP
·         Ciprofloxacin Injection, USP
·         Ciprofloxacin in 5% Dextrose Injection, USP
·         Clindamycin Injection, USP
·         Tobramycin Injection, USP
·         Tobramycin Injection, USP (Pediatric)
·         Tobramycin in 0.9% Sodium Chloride Injection
·         Vancomycin Hydrochloride for Injection, USP

CARDIOVASCULAR

·         Amimocaproic Acid Injection, USP
·         Amiodarone Hydrochloride Injection
·         Atropine Sulfate Injection, USP (Pediatric)
·         Atropine Sulfate Injection, USP (Adult)
·         Diltiazem Hydrochloride Injection
·         Diltiazem Hydrochloride for Injection
·         Dobutamine Injection, USP
·         Dobutamine in 5% Dextrose Injection, USP
·         Dopamine Hydrochloride Injection, USP
·         Dopamine Hydrochloride in 5% Dextrose Injection, USP
·         Enalaprilat Injection, USP
·         Epinephrine Injection, USP
·         Corlopam™ (Fenoldopam Mesylate Injection, USP)
·         Isuprel™ (Isoproterenol Hydrochloride Injection, USP)
·         Labetalol Hydrochloride Injection, USP
·         Levophed™ (Norepinephrine Bitartrate Injection, USP)
·         Lidocaine Hydrochloride Injection, USP (For Cardiac Use Only)
·         Lidocaine Hydrochloride and 5% Dextrose Injection, USP (For Cardiac Use Only)
·         Metoprolol Tartrate Injection, USP
·         Milrinone Lactate Injection in 5% Dextrose
·         Nitroglycerin in 5% Dextrose Injection
·         Plegisol™ (Cardioplegic Solution)
·         Procainamide Hydrochloride Injection, USP
·         Nitropress™ (Sodium Nitroprusside Injection)
·         Verapamil Hydrochloride Injection, USP

ANALGESICS

·         Alfentanil Injection, USP CII
·         Buprenorphine Hydrochloride Injection, CIII
·         Butorphanol Tartrate Injection, USP, CIV
·         Fentanyl Citrate Injection, USP, CII
·         Hydromorphone Hydrochloride Injection, USP, CII
·         Hydromorphone Hydrochloride Injection, USP, CII (High-Potency Formulation)
·         Ketorolac Tromethamine Injection, USP
·         Meperidine Hydrochloride Injection, USP, CII (for use with PCA)
·         Demerol™ (Meperidine Hydrochloride Injection, USP, CII)
·         Morphine Sulfate Injection, USP, CII (Preservative and Antioxidant Free)
·         Morphine Sulfate Injection, USP, CII, (Preservative-Free)(For PCA Use Only)
·         Morphine Sulfate Injection, USP, CII (Preservative-Free and contains an antioxidant)
·         Nalbuphine Hydrochloride Injection
·         Talwin™( Pentazocine Lactate Injection, USP, CIV)
·         Sufentanil Citrate Injection, USP, CII

ANTICOAGULANTS

·         Heparin Sodium Injection, USP
·         Heparin Sodium Injection, USP (Preservative-Free)
·         Heparin Sodium in 5% Dextrose Injection
·         Heparin Sodium in 0.45% Sodium Chloride Injection
·         Heparin Sodium in 0.9% Sodium Chloride Injection

ANTICONVULSANTS

·         Fosphenytoin Sodium Injection, USP
·         Levetiracetam Injection
·         Phenytoin Sodium Injection, USP
·         Antiemetic
·         Droperidol Injection, USP
·         Metoclopramide Injection, USP
·         Ondansetron Injection, USP
·         Promethazine Hydrochloride Injection, USP

ANTIHISTAMINE

·         Diphenhydramine Hydrochloride Injection, USP

ANTINEOPLASTICS

·         Bleomycin for Injection, USP
·         Carboplatin Injection
·         Cytarabine Injection
·         Dacarbazine for Injection, USP
·         Docetaxel Injection, USP
·         Epirubicin Hydrochloride Injection (Solution)
·         Epirubicin Hydrochloride for Injection (Lyophilized)
·         Fludarabine Phosphate for Injection, USP
·         Gemcitabine Injection (Solution)
·         Gemcitabine for Injection, USP (Lyopholized)
·         Irinotecan Hydrochloride Injection
·         Methotrexate Injection, USP
·         Mitoxantrone Injection, USP
·         Oxaliplatin Injection
·         Paclitaxel Injection
·         Nipent™ (Pentostatin for Injection)
·         Topotecan Injection
·         Vincristine Sulfate Injection, USP (Preservative-Free)
·         Vinorelbine Tartrate Injection

DILUENTS

·         Bacteriostatic 0.9% Sodium Chloride Injection, USP
·         Bacteriostatic Water for Injection, USP
·         5% Dextrose Injection, USP
·         0.45% Sodium Chloride Injection, USP
·         0.9% Sodium Chloride Injection, USP
·         Sterile Water for Injection, USP
·         Sterile Water for Injection, USP

DIURETICS

·         Bumetanide Injection, USP
·         Furosemide Injection, USP
·         Mannitol Injection, USP

HYPNOTICS

·         Amidate™ (Etomidate Injection, USP)
·         Propofol Injectable Emulsion 1% (contains Benzyl Alcohol)

LOCAL ANESTHETICS

·         Bupivacaine Hydrochloride Injection, USP
·         Bupivacaine Hydrochloride & Epinephrine Injection, USP (Bupivacaine Hydrochloride and Epinephrine 1:200,000 as the bitartrate)
·         Bupivacaine Spinal (Bupivacine in Dextrose, USP)
·         Lidocaine Hydrochloride Injection, USP
·         Lidocaine Hydrochloride Injection, USP (For Topical Use & Retrobulbar Injection)
·         Lidocaine Hydrochloride and 7.5% Dextrose Injection, USP (For Spinal Anesthesia)
·         Lidocaine Hydrochloride and Epinephrine Injection, USP (Lidocaine and Epinephrine 1:200,000)
·         Lidocaine Hydrochloride and Epinephrine Injection, USP (Lidocaine and Epinephrine 1:100,000)
·         Lidocaine Hydrochloride and Epinephrine 1:50,000 Injection, USP (For Dental Use)
·         Marcaine™ (Bupivacaine Hydrochloride Injection, USP)
·         Marcaine™ with Epinephrine 1:200,000 as the bitartrate (Bupivacaine Hydrochloride & Epinephrine Injection, USP)
·         Marcaine™ Spinal (Bupivacaine Hydrochloride in Dextrose Injection, USP)
·         Carbocaine™ (Mepivacaine Hydrochloride Injection, USP)
·         Mepivacaine Hydrochloride Injection, USP
·         Lidocaine Hyrochloride Topical Solution, USP (Preattached LTA™ Kit) Filled vial is preattached to injector and anatomically designed cannula. Features circumferential 360° spray pattern, 4 mL of Lidocaine Hydrochloride Topical Solution, USP, 4%

NEUROMUSCULAR BLOCKERS

·         Atracurium Besylate Injection, USP
·         PaNcuronium Bromide Injection
·         Rocuronium Bromide Injection
·         Succinylcholine Chloride Injection, USP (Quelicin™)

SEDATIVES

·         Diazepam Injection, USP, CIV
·         Lorazepam Injection, USP, CIV
·         Midazolam Injection, USP, CIV
·         Precedex™ (Dexmedetomidine HCl Injection)
·         Vecuronium Bromide for Injection
·         Precedex™ (Dexmedetomidine HCl Injection)
·         Precedex™ Concentrate (Dexmedetomidine HCl Injection) Precedex must be diluted in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. Precedex™ Premix (Dexmedetomidine HCl in 0.9% Sodium Chloride Injection) Now available — all the benefits of Precedex…

 

ONCOLOGY MEDICATIONS

Abbokinase (Urokinase)

NDC       00074-6145-02
00074-6109-05
00074-6111-01

Adriamycin PFS (Doxorubicin Hydrochloride)

NDC       00013-1236-91
00013-1246-91
00013-1256-79
00013-1266-83

Adriamycin RDF (Doxorubicin Hydrochloride)

NDC       00013-1086-97
00013-1096-91
00013-1106-79
00013-1116-83

Calcijex (Calcitrol)

NDC       00074-8110-31

Celestone Soluspan (Betamethasone Acetate, Betamethasone Sodium Phosphate)

NDC       00085-0566-05

DTIC-Dome (Decarbazine)

NDC       00026-8151-20

Epogen (Epotein Alpha)

NDC       55513-0267-10
55513-0148-10
55513-0144-10
55513-0283-10

Etoposide (Etoposide Injection)

NDC       00703-5653-01
00703-5656-01
00703-5657-01

Ethyol (Amifostine)

NDC       58178-0017-03

Intron-A (Interferon Alpha-2b)

NDC       00085-0647-05
00085-0120-02
00085-0571-02
00085-1110-01
00085-0285-02
00085-0539-01

Kytril (Granisetron Hydrochloride)

NDC       00004-0239-09
00004-0240-09
00004-0241-33
00004-0241-26

Lupron Depot (Leuprolide Acetate)

NDC       00300-3641-01
00300-3642-01
00300-3663-01
00300-3346-01
00300-3683-01

Leucovorin (Leucovorin Calcium)

NDC       63323-0710-50
63323-0710-00

Leukine (Sargramostim)

NDC       58406-0002-01
58406-0050-14

Neupogen (Filgrastim)

NDC       55513-0530-10
55513-0546-10

Procrit (Epotein Alpha)

NDC       59676-0302-01
59676-0302-02
59676-0303-01
59676-0303-02
59676-0304-01
59676-0304-02
59676-0310-01
59676-0310-02
59676-0312-01
59676-0320-01
59676-0340-01

Taxol (Paclitaxel)

NDC       00015-3475-30
00015-3476-30
00015-3479-11

Zofran (Ondansetron HCL)

NDC       00173-0442-02
00173-0442-00
00173-0461-00

PLASMA DERIVATIVES & RECOMBINANT PRODUCTS

Albumin

Albumin is a concentrated solution of protein which is obtained from healthy donors and administered intravenously to restore plasma volume due to loss by shock, trauma, surgery and burns.   Albumin is one of a group of simple proteins made by the liver.  Serum albumin is the main protein found in the blood (about 60% of the total).  It is responsible for much of the plasma colloidal osmotic pressure and serves as a transport protein.  Albumin is primarily supplied in vials of either 5% or 25% solution in sizes of 20mL, 50mL, 250mL or 500mL dependent upon solution percentage.

Albumin 5%

·         Albumin – Octapharma
o   Albumin 5%                        250mL   NDC       67467-0623-02
·         AlbuKed™ 5
o   AlbuKed™ 5%                    50mL     NDC       76125-0785-05
o   Albuked™ 5%                    250mL   NDC       76125-0785-25
·         AlbuRx® 5
o   AlbuRx® 5%                        250mL   NDC       44206-0310-25   (Human 5%)
o   AlbuRx® 5%                        500mL   NDC       44206-0310-50   (Human 5%)
·         Albutein® 5%
o   Albutein® 5%                     250mL   NDC       68516-5214-01
o   Albutein® 5%                     500mL   NDC       68516-5214-02
·         Buminate® 5%
o   Buminate® 5%                   250mL   NDC       0944-0491-01
o   Buminate® 5%                   500mL   NDC       0944-0491-02
·         Plasbumin®
o   Plasbumin® -5                   50mL     NDC       13533-685-20
o   Plasbumin® -5                   250mL   NDC       13533-685-25

Albumin 25%

·         Albumin – Octapharma
o   Albumin 25%                      50mL     NDC       67467-0643-01
·         AlbuKed™ 25
o   Albuked™ 25%                  20mL     NDC       76125-0784-20
o   Albuked™ 25%                  50mL     NDC       76125-0784-25
·         Albuminar® 25
o   Albuminar® -25                 20mL     NDC       00053-7680-01
o   Albuminar® -25                 100mL   NDC       00053-7680-33
·         AlbuRx® 25
o   AlbuRx® 25%                      50mL     NDC       44206-0251-05   (Human 25%)
o   AlbuRx® 25%                      100mL   NDC       44206-0251-10   (Human 25%)
·         Albutein® 25%
o   Albutein® 25%                  50mL     NDC       68516-5216-01
o   Albutein® 25%                   100mL   NDC       68516-5216-02
·         Buminate® 25%
o   Buminate 25%                   20mL     NDC       00944-0490-01
o   Buminate 25%                   50mL     NDC       00944-0490-02
o   Buminate 25%                   100mL   NDC       00944-0490-03
·         Flexbumin 25%
o   Flexbumin 25%                 50mL     NDC       00944-0493-01
o   Flexbumin 25%                 100mL   NDC       00944-0493-02
·         Plasbumin®
o   Plasbumin®-25                  20mL     NDC       13533-0684-16
o   Plasbumin®-25                  50mL     NDC       13533-0684-20
o   Plasbumin®-25                  100mL   NDC       13533-0684-71

Plasma Protein Fraction (PPF) 5%

·         Plasmanate® 5%
o   Plasmanate®5%                50mL     NDC       13533-0613-20
o   Plasmanate®5%                250mL   NDC       13533-0613-25

IVIG

Intravenous Immune Globulin (IVIG or IGIV) is a sterile solution of concentrated antibodies extracted from healthy donors which is administered intravenously. IVIG infusion therapy treats disorders of the immune system, such as ITP (Immune Thrombocytopenic Purpura) and PID (Primary Immune Deficiency disorders), disorders of the neurological system, such as CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) or to boost immune response to serious illness, and to treat immunosuppressed recipients of bone marrow transplants.

10% Liquid IVIG

·         PRIVIGEN®

PRIVIGEN® Immune Globulin Intravenous (Human), 10% Liquid is an intravenous Immune Globulin indicated for treatment of Primary immunodeficiency and Chronic immune thrombocytopenic purpura (ITP).
o   5 gram vial           NDC      44206-0436-90
o   10 gram vial        NDC      44206-0437-91
o   20 gram vial        NDC      44206-0438-92
o   40 gram vial        NDC      44206-0439-40

·         BIVIGAM™

BIVIGAM™ Immune Globulin Intravenous (Human), 10% Liquid is indicated for the treatment of patients with primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
o   5 gram vial           NDC       59730-6502-01
o   10 gram vial        NDC       59730-6503-01

·         FLEBOGAMMA® 10% DIF

FLEBOGAMMA ® 10% DIF is a human immune globulin intravenous (IGIV) that is indicated for the treatment of primary immune deficiency (PI) including the humoral defect in common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich syndrome.
o   5 gram vial           NDC      61953-0005-01
o   10 gram vial        NDC      61953-0005-02
o   20 gram vial        NDC      61953-0005-03

·         GAMMAGARD® LIQUID

GAMMAGARD® 10% Liquid is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.  GAMMAGARD LIQUID is indicated as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).
o   1 gram vial           NDC      00944-2700-02
o   2.5 gram vial       NDC      00944-2700-03
o   5 gram vial           NDC      00944-2700-04
o   10 gram vial        NDC      00944-2700-05
o   20 gram vial        NDC      00944-2700-06
o   30 gram vial        NDC      00944-2700-07

·         GAMUNEX® -C

GAMUNEX® -C 10% Liquid is an immune globulin injection (human) indicated for treatment of Primary Humoral Immunodeficiency (PI) (subcutaneous administration), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)
o   1 gram vial           NDC      13533-0800-12
o   2.5 gram vial       NDC      13533-0800-15
o   5 gram vial           NDC      13533-0800-20
o   10 gram vial        NDC      13533-0800-71
o   20 gram vial        NDC      13533-0800-24

·         GAMMAKED™

GAMMAKED™ 10% Liquid is an immune globulin injection (human) indicated for the treatment of Primary Humoral Immunodeficiency (PI)  (subcutaneous administration), Idiopathic Thrombocytopenic Purpura (ITP), Chronic Inflammatory Demyelinating Polyneuropathy  (CIDP)
o   1 gram vial           NDC      76125-0900-01
o   2.5 gram vial       NDC      76125-0900-25
o   5 gram vial           NDC      76125-0900-50
o   10 gram vial        NDC      76125-0900-10
o   20 gram vial        NDC      76125-0900-20

5% Liquid IVIG

·         FLEBOGAMMA®

FLEBOGAMMA® 5% DIF is an Immune Globulin Intravenous (Human) 5% preparation that is indicated for the treatment of Primary Immunodeficiency (PI) including the humoral immune defect in common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich syndrome.
o   2.5 gram vial       NDC       61953-0004-02
o   5 gram vial           NDC       61953-0004-03
o   10 gram vial        NDC       61953-0004-04
o   20 gram vial        NDC       61953-0004-05

·         OCTAGAM®

OCTAGAM® 5% Liquid is an immune globulin intravenous (human), 5% liquid, indicated for the treatment of primary immunodeficiency (PI), such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies.
o   5 gram vial           NDC       68209-0843-03
o   10 gram vial        NDC       68209-0843-04
o   2.5 gram vial       NDC       68209-0843-02

·         GAMMAPLEX®

GAMMAPLEX® 5% Liquid is indicated for the replacement therapy of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.  Gammaplex® is also indicated for the treatment of chronic immune thrombocytopenic purpura (ITP).
o   2.5 gram vial       NDC       64208-8234-01
o   5 gram vial           NDC       64208-8234-02
o   10 gram vial        NDC       64208-8234-03

Lyophilized IVIG

·         CARIMUNE®

CARIMUNE® NF is indicated for the maintenance treatment of patients with primary immunodeficiencies (PID, e.g., common variable immunodeficiency, X-linked agammaglobulinemia, severe combined immunodeficiency.  Carimune® NF is preferable to intramuscular Immune Globulin (Human) preparations in treating patients who require an immediate and large increase in the intravascular immunoglobulin level14, in patients with limited muscle mass, and in patients with bleeding tendencies for whom intramuscular injections are contraindicated. The infusions must be repeated at regular intervals.
o   3 gram vial           NDC       44206-0416-03
o   6 gram vial           NDC       44206-0417-06
o   12 gram vial        NDC       44206-0418-12

·         GAMMAGARD®
GAMMAGARD S/D is an immune globulin intravenous (Human), indicated for treatment of Primary Immunodeficiency (PI) in adults and pediatric patients two years of age or older, prevention of bacterial infections in hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CLL), prevention and/or control of bleeding in adult Chronic Idiopathic Thrombocytopenic Purpura (ITP) patients and prevention of coronary artery aneurysms associated with Kawasaki syndrome in pediatric patients.
o   5 gram                  NDC       00944-2655-03
o   10 gram                NDC       00944-2655-04

SUBCUTANEOUS IMMUNE GLOBULIN (SCIg)

Subcutaneous Immune Globulin (SCIg) is a sterile solution of concentrated, polyvalent immunoglobulin, extracted from healthy donors,  which is injected into the layer of skin known as the subcutis. Sometimes referred to as SubQ Immune Globulin, it is used to treat immune system disorders, to boost immune system response to serious illness, as well as in the regulation of certain autoimmune disorders.

Subcutaneous Immune Globulin 20%

·         HIZENTRA®
HIZENTRA® is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
o   5mL/1gram vial                 NDC       44206-0451-01
o   10mL/2 gram vial              NDC       44206-0452-02
o   20mL/4 gram vial              NDC       44206-0454-04

Subcutaneous Immune Globulin 10%

·         GAMUNEX®-C
GAMUNEX® -C is an immune globulin injection (human),  10% liquid indicated for treatment of Primary Humoral Immunodeficiency (PI) (subcutaneous administration), Idiopathic Thrombocytopenic Purpura (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIPD).
o   1 gram vial           NDC       13533-0800-12
o   2.5 gram vial       NDC       13533-0800-15
o   5 gram vial           NDC       13533-0800-20
o   10 gram vial        NDC       13533-0800-71
o   20 gram vial        NDC       13533-0800-24

·         GAMMAKED™
GAMMAKED™ is an immune globulin injection (human), 10% liquid indicated for the treatment of Primary Humoral Immunodeficiency (PI)  (subcutaneous administration), Idiopathic Thrombocytopenic Purpura (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy  (CIDP).
o   1 gram vial           NDC       76125-900-01
o   2.5 gram vial       NDC       76125-900-25
o   5 gram vial           NDC       76125-900-50
o   10 gram vial        NDC       76125-900-10
o   20 gram vial        NDC       76125-900-20

·         GAMMAGARD® LIQUID
GAMMAGARD® LIQUID is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.  GAMMAGARD LIQUID is also indicated as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).
o   1 gram vial           NDC       0944-2700-02
o   2.5 gram vial       NDC       0944-2700-03
o   5 gram vial           NDC       0944-2700-04
o   10 gram vial        NDC       0944-2700-05
o   20 gram vial        NDC       0944-2700-06
o   30 gram vial        NDC       0944-2700-07

HYPER IMMUNE GLOBULIN

Hyper Immune globulin is similar to Intravenous Immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen.  Injectable (High-Titer) Immune Globulin products have a high concentration of a specific antibody, promoting passive immunization by providing a high titer of a specific immune globulin. Hyper-immunes include immune globulins such as tetanus or hepatitis. Other injectables, such as vaccines, contain a specific antigen, promoting active immunization by stimulating the body’s own immune response.

Rho(D) Immune Globulin

·         RHOPHYLAC®
RHOPHYLAC® is indicated for supression of rhesus (Rh) isoimmunization in pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with Rh-incompatible pregnancy, including  routine antepartum and postpartum Rh prophylaxis, Rh prophylaxis in obstetric complications or invasive procedures, incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells (RBCs), immune thrombocytopenic purpura (ITP) and raising platelet counts in Rho(D)-positive, non-splenectomized adults with chronic ITP.
o   PFS Single Syringe            NDC       44206-0300-01
o   PFS 10 pack                         NDC       44206-0300-10

·         HYPERRHO® S/D
HYPERRHO® S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant, providing that the criteria detailed in the package insert are met.  HyperRHO® S/D Mini-Dose is recommended to prevent the isoimmunization of Rho(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks gestation provided that the criteria detailed in the package insert are met.
o   Full Dose                              NDC       13533-0631-02
o   Mini Dose (10 pack)        NDC       13533-0631-06

·         RHOGAM®
RHOGAM® is indicated for pregnancy and Other Obstetric Conditions in Rh-Negative Women, Unless the Father or Baby are Conclusively Rh Negative, pregnancy / deliver of an Rh-positive baby irrespective of the ABO groups of the mother and bab, incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells (RBC), ectopic pregnancy, antepartum fetal-maternal hemorrhage (suspected or proven) resulting from antepartum hemorrhage (e.g., placenta previa), amniocentisis, chorionic villus sampling, percutaneous umbilical blood sampling, other obstetrical manipulative procedure (e.g., version) or abdominal trauma, transfusion of Rh incompatible blood or blood products, prevention of Rh immunization in any Rh-negative person after incompatible transfusion of Rh-positive blood or blood products (e.g., red blood cells, platelet concentrates, granulocyte concentrates).
o   1 PFS Single Dose             NDC       00562-7805-01
o   5 PFS Single Dose             NDC       00562-7805-05
o   25 PFS Single Dose           NDC       00562-7805-25

·         MICRHOGAM®
MICRHOGAM® is indicated for pregnancy and Other Obstetric Conditions in Rh-Negative Women, Unless the Father or Baby are Conclusively Rh Negative, pregnancy / deliver of an Rh-positive baby irrespective of the ABO groups of the mother and bab, incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells (RBC), ectopic pregnancy, antepartum fetal-maternal hemorrhage (suspected or proven) resulting from antepartum hemorrhage (e.g., placenta previa), amniocentisis, chorionic villus sampling, percutaneous umbilical blood sampling, other obstetrical manipulative procedure (e.g., version) or abdominal trauma, transfusion of Rh incompatible blood or blood products, prevention of Rh immunization in any Rh-negative person after incompatible transfusion of Rh-positive blood or blood products (e.g., red blood cells, platelet concentrates, granulocyte concentrates).
o   1 PFS Single Dose             NDC       00562-7806-01
o   5 PFS Single Dose             NDC       00562-7806-05
o   25 PFS Single Dose           NDC       00562-7806-25

·         WINRHO® SDF
WINRHO® SDF Liquid is a Rho(D) Immune Globulin Intravenous (Human) indicated for immune Thrombocytopenic Purpura (ITP), raising platelet counts in Rho(D) positive , non-splenectomized children with chronic or acute ITP, adults with chronic ITP and children and adults with ITP secondary to HIV infection, suppression of Rhesus (Rh) Isoimmunization  Pregnancy and other obstetric conditions in non-sensitized, Rho(D) -negative women with an Rh-incompatible pregnancy including routine antepartum  and postpartum Rh prophylaxis, Rh prophylaxis in obstetric complications or invasive procedures and incompatible transfusions in RH0 (D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells (RBC’s).
o   300 mcg                               NDC       53270-3300-01
o   500 mcg                               NDC       53270-3500-01
o   1000 mcg                            NDC       53270-3100-01
o   3000 mcg                            NDC       53270-3000-01

Intramuscular Immune Globulin

•             GAMASTAN® S/D
GAMASTAN® S/D is indicated for Hepatitis A: The prophylactic value of GamaSTAN® S/D is greatest when given before or soon after exposure to hepatitis A.  GamaSTAN® S/D is not indicated in persons with clinical manifestations of Hepatitis A or in those exposed more than 2 weeks previously.  Measles (Rubeola): GamaSTAN® S/D should be given to prevent or modify measles in a susceptible person exposed fewer that 6 days previously. A susceptible person is one who has not been vaccinated and has not had measles previously.  GamaSTAN® S/D may be especially indicated for susceptible household contacts of measles patients, particularly contacts under 1 year of age, for whom the risk of complications is highest.  GamaSTAN® S/D and measles vaccine should not be given at the same time. If a child is older than 12 months and has received GamaSTAN® S/D, he should be given measles vaccine about 3 months later when the measles antibody titer will have disappeared.  If a susceptible child exposed to measles is immunocompromised, GamaSTAN® S/D should be  given immediately.  Children who are immunocompromised should not receive measles vaccine or any other live viral vaccine.  Varicella: Passive immunization against varicella in immunosuppressed patients is best accomplished by use of Varicella Zoster Immune Globulin (Human) [VZIG]. If VZIG is unavailable, GamaSTAN S/D, promptly given, may also modify varicella.  Rubella: The routine use of GamaSTAN® S/D for prophylaxis of rubella in early pregnancy is of dubious value and cannot be justified. Some studies suggest that the use of GamaSTAN® S/D in exposed, susceptible women can lessen the likelihood of infection and fetal damage; therefore, GamaSTAN® S/D may benefit those women who will not consider a therapeutic abortion.  Immunoglobulin Deficiency: In patients with immunoglobulin deficiencies, GamaSTAN® S/D may prevent serious infection. However, GamaSTAN® S/D may not prevent chronic infections of the external secretory tissues such as the respiratory and gastrointestinal tract.  Prophylactic therapy, especially against infections due to encapsulated bacteria, is effective in Bruton-type sex-linked, congenital agammaglobulinemia, agammaglobulinemia associated with thymoma, and acquired agammaglobulinemia.
o   2mL SDV                              NDC       13533-0635-04
o   10mL vial                              NDC       13533-0635-12

Hepatitis B Immune Globulin

•             HYPERHEP B® S/D
HYPERHEP B® S/D – Recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future HBV exposure for the person requiring treatment.  In all exposures, a regimen combining Hepatitis B Immune Globulin (Human) with hepatitis B Immune vaccine will provide both short-and long-term protection, will be less costly than the two-dose Hepatitis B Immune Globulin (Human) treatment alone, and is the treatment of choice. HyperHEP B® S/D is indicated for post-exposure prophylaxis in the following situations when the conditions listed in the PI are met:  Acute Exposure to Blood Containing HBsAg, Sexual Exposure to an HBsAg-positive Person, Household Exposure to Persons with Acute HBV Infection, HepaGam B®, Nabi HB®
o   HyperHEP B® syringe Neonatal PFS w/ safety     0.5mL   NDC       13533-0636-03
o   HyperHEP B® syringe      1mL                                                      NDC       13533-0636-02
o   HyperHEP B® vial              5mL                                                      NDC       13533-0636-05

·         HEPAGAM B™
HEPAGAM B™ is indicated for prevention of Hepatitis B recurrence following Liver Transplantation in HBsAg-positive liver transplant patients.  Post-exposure prophylaxis in the following settings: Acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons, household exposure to persons with acute HBV Infection.
o   1mL        NDC      53270-0052-01
o   5mL        NDC      53270-0051-01

·         NABI-HB®
NABI-HB® is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infection in the following settings when the conditions described in the PI are met: Acute Exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons, household exposure to persons with acute HBV infection.  Nabi-HB® is indicated for intramuscular use only.
o   1mL SDV              NDC       59730-4202-01
o   5mL SDV              NDC       59730-4203-01

Rabies Immune Globulin

•             HYPERRAB® S/D
HYPERRAB® S/D Rabies vaccine and HyperRAB® S/D should be given to all persons suspected of exposure to rabies with one exception: Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRAB® S/D should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given.  Recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the U.S. Public Health Service Advisory Committee on Immunization Practices (ACIP).  Every exposure to possible rabies infection must be individually evaluated;  the factors, as detailed in the PI, should be considered before specific anti-rabies treatment is initiated.
o   2mL vial                NDC       13533-0618-02
o   10mL vial              NDC       13533-0618-10

·         IMOGAM® Rabies-HT
IMOGAM® Rabies-HT Rabies Immune Globulin (Human) Heat Treated, IMOGAM® Rabies HT, is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with Rabies Vaccine prepared from human diploid cells (HDCV) in a pre-exposure or post-exposure treatment series should receive only vaccine. Persons who have been previously immunized with Rabies Vaccines other than HDCV, RVA (Rabies Vaccine Adsorbed), or PCEC (Purified Chick Embryo Cell Vaccine) vaccines should have confirmed adequate rabies antibody titers if they are to receive only vaccine.  IMOGAM® Rabies HT should be injected as promptly as possible after exposure along with the first dose of vaccine. If initiation of treatment is delayed for any reason, IMOGAM® Rabies HT and the first dose of vaccine should still be given, regardless of the interval between exposure and treatment. IMOGAM® Rabies HT may be given up to eight days after the first dose of vaccine was given.  Rabies virus is usually transmitted by the bite of a rabid animal (dog, bat, etc.) but can occasionally penetrate abraded skin contaminated with the saliva of infected animals. Progress of the virus after exposure is believed to follow a neural pathway and the time between exposure and clinical rabies is a function of the proximity of the bite (or abrasion) to the central nervous system and the dose of virus injected. The incubation is usually 2 to 6 weeks but can be longer. After severe bites about the face and neck and arms, it may be as short as 10 days. After initiation of the vaccine series (human diploid cell origin), it takes approximately one week for development of immunity to rabies; therefore, the value of immediate passive immunization with rabies antibodies in the form of Rabies Immune Globulin (Human) cannot be overemphasized.  Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the WHO and by the United States Public Health Service Advisory Committee on Immunization Practices (ACIP).  Each exposure to possible rabies infection must be individually evaluated. Local or state public health officials should be consulted if questions arise about the need for rabies prophylaxis.
o   2mL vial                NDC      49281-0190-20
o   10mL vial              NDC      49281-0190-10

Tetanus Immune Globulin

·         HYPERTET® S/D SYRINGE
HyperTET® S/D is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain.  It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus. A thorough attempt must be made to determine whether a patient has completed primary vaccination.  Patients with unknown or uncertain previous vaccination histories should be considered to have had no previous tetanus toxoid doses. Persons who had military service since 1941 can be considered to have received at least one dose, and although most of them may have not completed a primary series of tetanus toxoid, this cannot be assumed for each individual. Patients who have not completed a primary series may require tetanus toxoid and passive immunization at the time of the wound cleaning and debridement.
o   250 unit syringe               NDC       13533-0634-02

Cytomegalovirus Immune Globulin

•             CYTOGAM® CMV IVIG
Cytogam® CMV IVIG (Cytomegalovirus Immune Globulin Intravenous (Human)) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.  In transplants of these organs, other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.
o   2.5 gram vial                     NDC       44206-3101-01

COAGULATION PRODUCTS

FACTOR VIII

Recombinant

·         Helixate® FS
·         ADVATE®
·         Kogenate® FS
·         Recombinate
·         XYNTHA®

Plasma Derived

·         Koate®-DVI
·         Alphanate® AHF/VWF complex
·         Hemofil M AHF
·         Humate-P® AHF/VWF complex
·         Monoclate-P®

Containing vWF

·         Koate®-DVI
·         wilate® vWF / FVIII Complex
·         Alphanate® AHF/VWF complex
·         Humate-P® AHF/VWF complex
·         Stimate® Nasal Spray

FACTOR IX

·         AlphaNine® S/D
·         Bebulin®
·         BeneFIX®
·         Mononine®
·         Profilnine®S/D

FACTOR VIIa

·         NovoSeven® RT

ANTI INHIBITOR COMPLEX

·         FEIBA NF